AZN - AlloVir Seeks IPO For Anti-Viral Pipeline Development
Quick Take
AlloVir (ALVR) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement.
The company is a mid-stage clinical biopharma firm developing treatments for various virus infections.
ALVR is seeking funding to advance its lead candidate’s multiple programs into pivotal trials.
I’ll provide an update when we learn IPO pricing and valuation details.
Company & Technology
Cambridge, Massachusetts-based AlloVir was founded to advance a pipeline of treatment candidates for viruses, including a preclinical stage program for Covid19 virus.
Management is headed by